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Abstract
Background: Site performance is key to the success of large multicentre randomised trials. A standardised set of
clear and accessible summaries of site performance could facilitate the timely identification and resolution of
potential problems, minimising their impact.
The aim of this study was to identify and agree a core set of key performance metrics for managing multicentre
randomised trials.
Methods: We used a mixed methods approach to identify potential metrics and to achieve consensus about the final
set, adapting methods that are recommended by the COMET Initiative for developing core outcome sets in health care.
We used performance metrics identified from our systematic search and focus groups to create an online Delphi survey.
We invited respondents to score each metric for inclusion in the final core set, over three survey rounds. Metrics scored as
critical by ≥70% and unimportant by <15% of respondents were taken forward to a consensus meeting of
representatives from key UK-based stakeholders. Participants in the consensus meeting discussed and voted on each
metric, using anonymous electronic voting. Metrics with >50% of participants voting for inclusion were retained.
Results: Round 1 of the Delphi survey presented 28 performance metrics, and a further six were added in round 2. Of
294 UK-based stakeholders who registered for the Delphi survey, 211 completed all three rounds.
At the consensus meeting, 17 metrics were discussed and voted on: 15 metrics were retained following survey round 3,
plus two others that were preferred by consensus meeting participants. Consensus was reached on a final core set of
eight performance metrics in three domains: (1) recruitment and retention, (2) data quality and (3) protocol compliance. A
simple tool for visual reporting of the metrics is available from the Nottingham Clinical Trials Unit website.
Conclusions: We have established a core set of metrics for measuring the performance of sites in multicentre
randomised trials. These metrics could improve trial conduct by enabling researchers to identify and address problems
before trials are adversely affected. Future work could evaluate the effectiveness of using the metrics and reporting tool.
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Background
Large multicentre randomised trials are complex pro-
jects. A key risk to their successful delivery is the per-
formance of trial sites in recruiting and retaining
participants, and in collecting complete high-quality data
in a timely manner. Standardising the collection, report-
ing and monitoring of data relevant to site performance
has the potential to improve the effective and efficient
oversight of trial conduct [1–4].
Numerous variables or performance metrics can be
measured to assess site performance. Measures of site per-
formance should deliver meaningful, actionable informa-
tion that can be compared within and between sites to
initiate remedial action if necessary. A standardised set of
clear and easily accessible summaries of site performance
could facilitate the timely identification and resolution of
problems, minimising their impact. Although researchers
monitor data such as participant accrual, case report form
returns, data quality, missing outcome data and serious
protocol violations or breaches of good clinical practice,
to our knowledge, no work has been conducted to estab-
lish a consensus on a core set of metrics for monitoring
performance of sites in non-commercial clinical trials.
Without a consensus, researchers may focus on too many
or uninformative indicators. To be manageable and retain
focus on items that really matter, a standardised set of site
performance metrics would ideally number around eight
to 12 items [1], and would be presented within a tool that
could be easily monitored by a trial manager.
The aim of this study was to develop a standardised set
of metrics for monitoring the performance of sites follow-
ing their initiation and opening to patient recruitment in
multicentre randomised trials. A further objective was to
develop a visual display tool for reporting metric data.
Methods
We used three focus groups of stakeholders (paper in
preparation) and a systematic literature review to iden-
tify site performance metrics [5]. To achieve consensus
on the final standardised set of metrics, we used a
two-stage Delphi process comprising a survey followed
by a consensus meeting of UK-based stakeholders.
Delphi Survey
We identified 117 performance metrics from 21 eligible
studies in the systematic literature review. Following initial
analysis, we excluded 30 metrics judged as lacking clarity,
unrelated to individual site performance, too specific to an
individual trial methodology or pertaining to clinical out-
comes rather than trial performance (Additional file 1).
This left 87 for further consideration. The 32 participants
in the three focus groups identified a further 19 metrics.
Following deduplication and further removal of metrics
considered unrelated to site performance, the remaining
list of 28 metrics (Additional file 2) were organised into
four thematic domains: (1) recruitment and retention, (2)
data quality, (3) protocol compliance and (4) staff. These
were used to create an online Delphi survey using the soft-
ware COMET Delphi Manager [6].
Panel size and membership
As there is no standard method for calculating the sample
size for Delphi processes, we used a pragmatic approach
based on practicality and time available [2, 4]. The aim was
to recruit the largest panel possible, encouraging individuals
from each stakeholder group to participate via email invita-
tions to the online survey. The stakeholder groups were:
 chief investigators
 members of the UK Clinical Research Network
 clinical trials unit (CTU) directors
 representatives of the main UK clinical trial funding
bodies
 operations managers and directors
 clinical trial quality assurance managers
 research associates, fellows and academics
 research delivery managers
 trial managers and coordinators
 sponsors
 statisticians
 trial steering committee members
Recruitment of the panel
Clinical trials researchers were contacted through the UK
Clinical Research Collaboration CTU Network and the UK
Trial Managers’ Network. Representatives of the National
Institute of Health Research (NIHR, a major funder of UK
clinical trials), sponsors, chief investigators and UK Clinical
Research Network representatives were identified through
members of the project team, key contacts within the NIHR
and the Trial Conduct Working Group of the Medical Re-
search Council. The survey was also publicised on the Trial
Forge website [7] and in a poster presentation at the 4th
International Clinical Trials Methodology Conference [8].
Respondents were asked to complete the survey individually
and to share the invitation with interested colleagues. Cri-
teria for eligibility to complete the survey were being based
in the UK and having at least three years’ experience of
working in clinical trials.
Distributing the Delphi survey
An email invitation to the three-round Delphi survey
contained a brief explanation of the study, emphasising
the importance of completing all three rounds [3], an es-
timate of the time needed to complete each round
(15 min) and a hyperlink to register with the survey. We
aimed to complete each survey round within four weeks.
Non-responders were sent automated reminders after
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one and two weeks, and a personalised email at the end
of week 3. Rounds were extended by a few days if re-
quested by participants to enable completion. Respon-
dents were informed they would be entered into a prize
draw if they completed all three rounds.
Upon registration, participants were asked to confirm
that they were based in the UK and had at least three
years’ experience working in clinical trials. They were
asked to give their geographical region in the UK and their
primary professional role. Participants’ names and contact
details were recorded so that personalised reminders to
complete the survey could be sent. However, the survey
software prevented any individual survey responses being
linked to individual names or contact details.
Conducting the Delphi survey
One thematic domain was presented per question page.
Participants were asked to score each metric according to
the importance of including it in a core set of essential met-
rics for monitoring the performance of sites during a trial.
The Grading of Recommendations Assessment Develop-
ment and Evaluation (GRADE) scale was used, which sug-
gests a 9-point Likert scale (1 to 9) to rank importance [4].
Scores of 7 to 9 denote metrics of critical importance,
scores of 4 to 6 are important but not critical, and scores of
1 to 3 are deemed not important. An option for unable to
score (10) and a space to provide optional feedback on rea-
sons for allocating particular scores were included. Partici-
pants could nominate additional metrics in round 1 to be
included in round 2. New metrics were added to the list for
round 2 if two or more participants suggested its inclusion,
and it was not deemed to duplicate or overlap significantly
with any other metric already in the survey [9].
Respondents were considered as a single panel. All
round 1 metrics were carried forward to subsequent
rounds. In rounds 2 and 3, each participant was pre-
sented with the distribution of scores from all partici-
pants in the previous round alongside their own score
for each metric. Participants were asked to consider the
responses from the other participants and review their
score, either confirming or changing it. A space was pro-
vided for participants to explain their reasons for chan-
ging an individual score. Invitation to participate in
rounds 2 and 3 was contingent upon completing the
preceding round, as participants were always presented
with their own scores from the previous round.
To investigate potential attrition bias [4, 10], we com-
pared round 1 item mean scores and the percentage of
respondents scoring each metric as critical for partici-
pants who completed only round 1 with those of partici-
pants who went on to complete round 2. We similarly
compared round 2 data for participants who completed
only rounds 1 and 2 with those participants who went
on to complete round 3.
Consensus criteria
We used the definitions of consensus described in
Table 1 [4, 11]. Inclusion of an item in the subset to be
discussed at the consensus meeting required agreement
by the majority of survey participants regarding the crit-
ical importance of the metric, with only a minority con-
sidering it unimportant.
Consensus meeting
Representatives of UK-based stakeholder groups and mem-
bers of the study team were invited to attend a consensus
meeting (September 2017). Prior to the meeting, we sent
participants summary statistics for all 34 metrics from the
Delphi survey. Ahead of the consensus meeting, partici-
pants were asked to review all the metrics that had reached
the consensus in status following the survey, as only these
metrics would be discussed and voted on during the meet-
ing. Anyone wishing to make a case for discussion of any of
the remaining metrics were given the opportunity to do so
before the start of the meeting. At the consensus meeting,
each metric was discussed in turn, and participants voted
for its inclusion in the final core set using an anonymous
electronic voting system. Metrics with >50% of participants
voting for its inclusion were retained.
Results
Delphi Survey
Figure 1 summarises the Delphi study. Data were col-
lected for the three rounds of the Delphi survey between
June and September 2017. Of 294 people who registered
for the survey, 277/294 (94%) completed round 1, 251/
277 (91%) completed round 2 and 211/277 (76%) com-
pleted round 3. The within-round completion rate for
round 3 was 211/251 (84%). Of the original 294, 280
(95%) had at least three years’ experience of working in
clinical trials.
Table 2 shows the participation in each round of the
Delphi survey by stakeholder group. Some participants
represented more than one group, but are described
here in their main role. Over half of all participants
were involved in trial management (senior trial man-
ager, project lead, manager, trial coordinator, or trial or
research manager). The next largest group was chief in-
vestigators (13% in round 3). Although 66 participants
who completed round 1 did not complete round 3, at-
trition appeared to be reasonably proportionate across
all the stakeholder groups. Of 277 participants who
completed round 1, 263 (95%) reported having at least
three years’ experience working in clinical trials, com-
pared with 200/211 (95%) who completed all three
rounds. There was no evidence of attrition bias between
rounds in terms of differences in metric scores between
participants who did or did not complete subsequent
survey rounds (Additional files 3 and 4).
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The geographical region providing the largest group of
participants who completed all three rounds was the
East Midlands (22%), followed by London (15%) and the
North-West England (12%). Other responses in round 3
were from: South-East England (10%), Scotland (8%),
South-West England (8%), Yorkshire and Humber (6%),
West Midlands (6%), North-East England (5%), Wales
(4%) and Northern Ireland (1%).
Table 3 summarises the scores for each metric by Delphi
survey round for the 211 participants who completed all
three rounds and the outcome of the consensus meeting.
Round 1
Six metrics (numbered 1, 13, 21, 23, 28 and 31 in Table 3)
reached the criterion for consensus in in round 1. No met-
rics were assigned a consensus out score. All 28 original
metrics were carried forward to round 2 and six new
metrics were added after round 1, following participants’
nominations. These were in the domains recruitment and
retention (metrics 5–8 and 14) and staff (metric 34).
Round 2
Ten metrics (numbers 1, 10, 13, 15, 16, 18, 21, 23, 28 and
31, Table 3) reached the criterion for consensus in in
round 2. All 34 metrics were carried forward to round 3.
Round 3
Altogether, 15 metrics (numbers 1, 8, 9, 10, 13, 14, 15, 16,
18, 21, 23, 27, 28, 29 and 31, Table 3) in three domains
achieved the criterion for consensus in by the end of
round 3 and were taken forward to the consensus meet-
ing. No metrics from the staff domain were taken forward
to the meeting. The reasons that participants reported for
changing their scores between rounds related to further
reflection and being influenced by the scores of others.
None of the metrics reached the criterion for consensus
out in any of the three survey rounds.
Consensus meeting
In total, 35 UK-based stakeholders were invited to the
consensus meeting, of whom 20 accepted and 16
attended. Participants represented trial managers, data
managers, statisticians, quality assurance managers, CTU
directors, chief investigators, research fellows, research
networks and research funders. In addition, nine members
of the study team attended, of whom seven voted, giving a
total of 23 voting participants.
In addition to the 15 metrics reaching the criterion
for inclusion after round 3 of the Delphi survey, a
further two metrics (numbers 7 and 26) were dis-
cussed and voted on at the meeting. This was because
several participants expressed a preference for these
when metrics 8 and 23 were considered. There was a
high level of agreement among participants. Of the 17
metrics that were discussed, 13 received over 75% of
votes for either inclusion or exclusion from the final
set (Table 3).
Eight metrics were included in the final core set:
three each in the domains recruitment and retention
and data quality, and two in protocol compliance
Table 1 Definition of consensus
Consensus classification Description Definition
Consensus in Consensus that the metric should be
included in the performance metric set
≥70% participants scoring 7 to 9
and < 15% participants scoring 1
to 3
Consensus out Consensus that the metric should not be
included in the performance metric set
≥70% participants scoring 1 to 3
and < 15% of participants scoring
7 to 9
No consensus Uncertainty about the importance of the
metric
Anything else
Source: [11]
Fig. 1 Summary results of Delphi survey and consensus meeting
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(Table 4). The final wording for some of the metrics
or the expanded definitions were altered to improve
clarity following discussion at the consensus meeting.
Table 4 shows the final versions and a comparison
with the original versions.
Reporting tool
To support use of the core set of metrics, we have cre-
ated a simple tool in Microsoft Excel, using a traffic light
warning system to indicate potential problems (Fig. 2).
The traffic light colours for each metric are linked to a
set of thresholds. For example, when the percentage of
participants with at least one protocol violation at a site
is higher than 10%, this triggers a red traffic light. These
thresholds are set by each trial team and may be quite
different for different studies. The tool contains some
default thresholds, but these are arbitrary and for illus-
tration only. There are no accepted levels for any of
them, although use of the tool may lead to some ac-
cepted values emerging. There may also be situations
where a threshold changes during a trial. For example,
an individual site’s current recruitment target could be
reduced as the trial as a whole approaches its recruit-
ment target and the certainty of meeting the overall
sample size becomes clearer. The tool is freely available
from the Nottingham Clinical Trials Unit website [12].
Discussion
Using a mixed-methods approach, we achieved consen-
sus on a core set of eight metrics for monitoring the per-
formance of sites in multicentre randomised trials. The
core set includes three metrics on recruitment and re-
tention, three on data quality and two on protocol
compliance. No metrics from the staff domain were in-
cluded in the final set. To our knowledge, this is the first
study that has attempted to identify a core set of key
performance metrics for monitoring the conduct of clin-
ical trials.
It is unsurprising that the number of participants re-
cruited at sites was deemed critical for inclusion
throughout the Delphi survey and supported unani-
mously at the consensus meeting. However, it is also
notable that none of the 34 metrics achieved the criter-
ion for consensus out in the survey, suggesting recogni-
tion by respondents that the ‘health’ of a multicentre
randomised trial is multifaceted. Underlying problems
with staff training, capacity, equipoise, integration of the
trial into the clinical pathway or trial processes being in-
convenient or time-consuming for participants could be
reflected in several of the metrics included in the final
set. If not addressed, these problems may affect patient
safety, increase the risk of bias, or reduce the generalis-
ability or statistical power.
Our study has several strengths. For the survey, we
recruited a large sample of stakeholders with a wide
range of roles in clinical trials from throughout the UK.
This is important if the core set of metrics is to have
credibility and relevance among potential users. Attri-
tion in successive survey rounds diminishes group size.
This can result in a false impression of how much con-
sensus really exists [4], and may be due to participants
losing interest, having insufficient time or holding mi-
nority views [13]. Over 75% of participants who com-
pleted round 1 went on to complete rounds 2 and 3,
and there was no evidence of attrition bias, either in
terms of different stakeholder groups or in mean scores
Table 2 Delphi survey participation by stakeholder group
Role All Registered Round 1 Round 2 Round 3
n % of total n % of total n % of total n % of total % retained from round 1
Senior trial manager, project lead or manager 56 19.0 52 18.8 49 19.5 40 19.0 77
Trial or research manager 52 17.7 51 18.4 46 18.3 40 19.0 78
Trial coordinator 48 16.3 44 15.9 37 14.7 26 12.3 59
Chief investigator 34 11.6 32 11.6 29 11.6 27 12.8 84
Academic or research associate or fellow 18 6.1 18 6.5 17 6.8 16 7.6 89
Statistician 18 6.1 17 6.1 16 6.4 14 6.6 82
Operations manager or director 14 4.8 13 4.7 13 5.2 10 4.7 77
UK Clinical Research Network member 12 4.1 12 4.3 11 4.4 9 4.3 75
Clinical Trials Unit director 8 2.7 7 2.5 6 2.4 5 2.4 71
Quality assurance manager 8 2.7 8 2.9 8 3.2 8 3.8 100
Research delivery manager 4 1.4 3 1.1 2 0.8 2 0.9 67
Funder 2 0.7 2 0.7 2 0.8 2 0.9 100
Other 20 6.8 18 6.5 15 6.0 12 5.7 67
Total 294 100 277 100 251 100 211 100 76
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Table 3 Summary of item scores by survey round and outcome of consensus meeting
Metric and domain Round 1 scores Round 2 scores Round 3 scores % of
consensus
meeting
participants
voting to
retain item
1–3 4–6 7–9 10 1–3 4–6 7–9 10 1–3 4–6 7–9 10
n (%) respondents per rating category (1-3 ‘not important’, 4-6
‘important but not critical’, 7-9 ‘critical’, 10 unable to score)
Recruitment
and
retention
1. Total actual recruitment versus
total target recruitment a,c
1
(0.5)
36
(17.1)
172
(81.5)
2
(0.9)
0 16
(7.6)
194
(91.9)
1
(0.5)
0 14
(6.6)
197
(93.4)
0 100
2. Time from the site opening to
first participant randomised
8
(3.8)
108
(51.2)
94
(44.5)
1
(0.5)
3
(1.4)
118
(55.9)
90
(42.7)
0 5
(2.4)
126
(59.7)
80
(37.9)
0
3. Number of days/weeks since the
most recent participant was
randomised
21
(10.0)
112
(53.1)
77
(36.5)
1
(0.5)
12
(5.7)
142
(67.3)
57
(27.0)
0 11
(5.2)
155
(73.5)
45
(21.3)
0
4. Percentage of potential
participants screened who have
been randomised
4
(1.9)
88
(41.7)
117
(55.5)
2
(0.9)
2
(0.9)
83
(39.3)
125
(59.2)
1
(0.5)
0 76
(36)
134
(63.5)
1
(0.5)
5. Percentage of potential
participants who could have been
screened, who were screened
– – – – 13
(6.2)
97
(46.0)
92
(43.6)
9
(4.3)
10
(4.7)
90
(42.7)
103
(48.8)
8
(3.8)
6. Percentage of potential
participants screened who were
eligible
– – – – 9
(4.3)
106
(50.2)
93
(44.1)
3
(1.4)
6
(2.8)
110
(52.1)
92
(43.6)
3
(1.4)
7. Percentage of potential
participants eligible who have
consented b,c
– – – – 8
(3.8)
81
(38.4)
119
(56.4)
3
(1.4)
3
(1.4)
77
(36.5)
128
(60.7)
3
(1.4)
95
8. Percentage of potential
participants who have consented
and have been randomiseda
– – – – 5
(2.4)
71
(33.6)
131
(62.1)
4
(1.9)
2
(0.9)
57
(27)
150
(71.1)
2
(0.9)
35
9. Percentage of randomised
participants who have withdrawn
consent to continue in the studya,c
8
(3.8)
76
(36.0)
125
(59.2)
2
(0.9)
4
(1.9)
60
(28.4)
147
(69.7)
0 4
(1.9)
46
(21.8)
161
(76.3)
0 83
10. Percentage of randomised
participants lost to follow-upa
10
(4.7)
59
(28.0)
140
(66.4)
2
(0.9)
3
(1.4)
38
(18)
169
(80.1)
1
(0.5)
3
(1.4)
24
(11.4)
183
(86.7)
1
(0.5)
22
11. Percentage of screening logs
returned on time out of all those
that should have been returned
40
(19.0)
135
(64.0)
33
(15.6)
3
(1.4)
29
(13.7)
159
(75.4)
22
(10.4)
1
(0.5)
23
(10.9)
167
(79.1)
20
(9.5)
1
(0.5)
12. Percentage of screening items
completed of those required
32
(15.2)
105
(49.8)
67
(31.8)
7
(3.3)
20
(9.5)
114
(54)
72
(34.1)
5
(2.4)
18
(8.5)
117
(55.5)
72
(34.1)
4
(1.9)
13. Percentage of randomised
participants with a consent form
that is incomplete or inaccuratea
11
(5.2)
51
(24.2)
148
(70.1)
1
(0.5)
8
(3.8)
31
(14.7)
172
(81.5)
0 9
(4.3)
14
(6.6)
187
(88.6)
1
(0.5)
13
14. Percentage of all expected forms
that have been receiveda
8
(3.8)
69
(32.7)
128
(60.7)
6
(2.8)
4
(1.9)
50
(23.7)
154
(73)
3
(1.4)
39
15. Percentage of randomised
participants with any issues or
problems with consenta
10
(4.7)
68
(32.2)
129
(61.1)
4
(1.9)
6
(2.8)
53
(25.1)
150
(71.1)
2
(0.9)
4
(1.9)
34
(16.1)
169
(80.1)
4
(1.9)
26
16. Percentage of randomised
participants for whom
documentation of consent is
missing from their medical recordsa
15
(7.1)
69
(32.7)
123
(58.3)
4
(1.9)
9
(4.3)
47
(22.3)
154
(73)
1
(0.5)
7
(3.3)
31
(14.7)
172
(81.5)
1
(0.5)
0
Data quality 17. Percentage of randomised
participants with the time between
data collection and either data entry
(electronic case report form) or
central receipt of paper case report
form within the target timeframe
12
(5.7)
129
(61.1)
66
(31.3)
4
(1.9)
8
(3.8)
156
(73.9)
45
(21.3)
2
(0.9)
7
(3.3)
170
(80.6)
32
(15.2)
2
(0.9)
18. Percentage of randomised
participants with a query/queries for
primary outcome data a,c
4
(1.9)
59
(28.0)
145
(68.7)
3
(1.4)
3
(1.4)
36
(17.1)
170
(80.6)
2
(0.9)
4
(1.9)
23
(10.9)
182
(86.3)
2
(0.9)
65
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Table 3 Summary of item scores by survey round and outcome of consensus meeting (Continued)
Metric and domain Round 1 scores Round 2 scores Round 3 scores % of
consensus
meeting
participants
voting to
retain item
1–3 4–6 7–9 10 1–3 4–6 7–9 10 1–3 4–6 7–9 10
n (%) respondents per rating category (1-3 ‘not important’, 4-6
‘important but not critical’, 7-9 ‘critical’, 10 unable to score)
19. Percentage of randomised
participants with query/queries for
secondary outcome data
16
(7.6)
128
(60.7)
65
(30.8)
2
(0.9)
8
(3.8)
156
(73.9)
46
(21.8)
1
(0.5)
8
(3.8)
162
(76.8)
40
(19)
1
(0.5)
20. Time taken between sending a
data query and resolution of the
query
17
(8.1)
140
(66.4)
52
(24.6)
2
(0.9)
10
(4.7)
164
(77.7)
36
(17.1)
1
(0.5)
9
(4.3)
167
(79.1)
34
(16.1)
1
(0.5)
21. Percentage of randomised
participants with complete data for
primary and important secondary
outcomesa,c
2(0.9) 44
(20.9)
163
(77.3)
2
(0.9)
1
(0.5)
20
(9.5%)
189
(89.6)
1
(0.5)
1
(0.5)
11
(5.2)
198
(93.8)
1
(0.5)
96
22. Percentage of randomised
participants with complete data
3
(1.4)
85
(40.3)
120
(56.9)
3
(1.4)
0 88
(41.7)
122
(57.8)
1
(0.5)
0 91
(43.1)
119
(56.4)
1
(0.5)
23. Percentage of unresolved
serious adverse event queries > 30
calendar days from the date the
query was generated a
3
(1.4)
44
(20.9)
163
(77.3)
1
(0.5)
1
(0.5)
24
(11.4)
186
(88.2)
0 1
(0.5)
12
(5.7)
198
(93.8)
0 9
24. Total number of adverse events
and serious adverse events reported
per number of randomised
participants
32
(15.2)
101
(47.9)
74
(35.1)
4
(1.9)
19
(9)
130
(61.6)
59
(28.0)
3
(1.4)
17
(8.1)
138
(65.4)
53
(25.1)
3
(1.4)
25. Number of serious adverse
events reported per number of
randomised participants
25
(11.8)
84
(39.8)
98
(46.4)
4
(1.9)
16
(7.6)
90
(42.7)
102
(48.3)
3
(1.4)
15
(7.1)
102
(48.3)
91
(43.1)
3
(1.4)
26. Number of adverse events
reported per number of randomised
participants b,c
40
(19)
106
(50.2)
60
(28.4)
5
(2.4)
27
(12.8)
136
(64.5)
45
(21.3)
3
(1.4)
24
(11.4)
148
(70.1)
36
(17.1)
3
(1.4)
81
Protocol
compliance
27. Percentage of randomised
participants with at least one
protocol violation a,c
6
(2.8)
78
(37)
124
(58.8)
3
(1.4)
1
(0.5)
64
(30.3)
145
(68.7)
1
(0.5)
0 47
(22.3)
163
(77.3)
1
(0.5)
76
28. Percentage of randomised
participants receiving allocated
intervention as intended per
protocol a,c
2
(0.9)
48
(22.7)
158
(74.9)
3
(1.4)
0 19
(9.0)
191
(90.5)
1
(0.5)
0 11
(5.2)
199
(94.3)
1
(0.5)
100
29. Number of missed visits per
number of randomised participants a
7
(3.3)
93
(44.1)
107
(50.7)
4
(1.9)
5
(2.4)
75
(35.5)
128
(60.7)
3
(1.4)
4
(1.9)
52
(24.6)
152
(72)
3
(1.4)
10
30. Number of late visits per
number of randomised participants
18
(8.5)
128
(60.7)
61
(28.9)
4
(1.9)
10
(4.7)
157
(74.4)
41
(19.4)
3
(1.4)
9
(4.3)
162
(76.8)
37
(17.5)
3
(1.4)
31. Number of critical or major audit
findings per number of randomised
participants a
6
(2.8)
43
(20.4)
152
(72)
10
(4.7)
4
(1.9)
23
(10.9)
179
(84.8)
5
(2.4)
3
(1.4)
14
(6.6)
190
(90)
4
(1.9)
0
Staff 32. Number of contacts from site
staff to the central trial team within
a given time period
79
(37.4)
112
(53.1)
14
(6.6)
6
(2.8)
76
(36)
124
(58.8)
6
(2.8)
5
(2.4%)
81
(38.4)
120
(56.9)
6
(2.8)
4
(1.9)
33. Time between protocol
amendment being sent and
principal investigator sign-off
22
(10.4)
110
(52.1)
73
(34.6)
6
(2.8)
16
(7.6)
127
(60.2)
65
(30.8)
3
(1.4)
15
(7.1)
140
(66.4)
53
(25.1)
3
(1.4)
34. Cumulative number of staff
included on the delegation of
duties log
– – – – 105
(49.8)
87
(41.2)
12
(5.7)
7
(3.3)
116
(55.0)
83
(39.3)
7
(3.3)
5
(2.4)
1–3 not important, 4–6 important but not critical, 7–9 critical and 10 unable to score
Scores shown for the 211 participants who completed all three rounds of the Delphi survey. Cells containing a dash indicate metrics that were added at round 2
and therefore not scored in round 1
aMetrics (n = 15) reaching consensus in status after survey round 3 and taken forward to the consensus meeting
b Metrics 7 and 26 were also discussed and voted on at the meeting
cMetrics receiving > 50% of the vote at the meeting and retained in the final set
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of previous rounds. To facilitate use of the core set of
performance metrics, we have developed a simple,
user-friendly reporting tool in Microsoft Excel, which
uses red, amber and green indicators based on thresh-
olds for each metric, as determined by the trial team.
This provides an at a glance performance check within
and between trial sites, and could be used to comple-
ment existing trial management systems and data that
are presented and discussed at regular trial manage-
ment group meetings. Moreover, by using Excel, trials
teams can modify the tool as they see fit to meet their
own requirements.
Limitations
There are also some limitations with our study. Al-
though Delphi methods have been used successfully to
develop core outcome sets and quality indicators in
health-related research [2–4, 10, 14], there is no gold
standard method for achieving consensus, and a differ-
ent methodology may have produced a different final set
of metrics [4, 15, 16].
Survey recruitment included a snowball sampling
technique and participation was voluntary. Trial man-
agers or those in similar roles made up the largest
survey participant group, comprising half of the re-
spondents who completed all three rounds. One could
argue that this group have the greatest day-to-day
role in monitoring site performance in multicentre
randomised trials and therefore, should be strongly
represented in the survey. However, even with half of
survey participants in other roles, including senior
positions, it is possible that the metrics selected for
the consensus meeting reflect those considered most
important by the dominant participant group.
Table 4 Recommended core set of site performance metrics (n = 8) retained following the consensus meeting
Domain Metric: original wording Definition: original wording Metric: amended wording Definition: amended wording
Recruitment
and
retention
1. Total actual recruitment
versus total target
recruitment (%)
The actual number of participants
recruited into the trial by the site,
versus the target number that was
contractually agreed with the site
prior to the trial commencing
Current actual recruitment
versus target recruitment
(%)
The actual number of participants
recruited into the trial by the site, at
the time of monitoring, versus the
target number that was
contractually agreed with the site
prior to the trial commencing
7. Percentage of potential
participants eligible who
have consented
The percentage of potential
participants who were eligible to
participate in the trial and who
consented to participate
Percentage of eligible
individuals who have
consented
The percentage of individuals who
were eligible to participate in the
trial and who consented to
participate
9. Percentage of
randomised participants
who have withdrawn
consent to continue
The percentage of randomised
participants who have withdrawn
their consent to any further
participation in the trial at the site.
Collection of any further follow up
data is therefore not attempted
Data quality 18. Percentage of
randomised participants
with a query for primary
outcome data
The percentage of randomised
participants at the site for whom the
central trial team has sent one or
more queries relating to the primary
outcome data back to the site staff
21. Percentage of
randomised participants
with complete data for
primary and important
secondary outcomes
The percentage of randomised
participants at the site with outcome
data complete for both the primary
outcome and all the agreed
important secondary outcomes
Percentage of expected
participants with
complete data for primary
and important secondary
outcomes
26. Number of adverse
events reported per
number of randomised
participants
Number of Adverse Events reported
per number of randomised
participants at the site
Percentage of randomised
participants with at least
one adverse event
reported
The percentage of randomised
participants at the site who have
reported at least one adverse event
Protocol
compliance
27. Percentage of
randomised participants
with at least one protocol
violation
The percentage of randomised
participants at the site with any
protocol violation/s, as defined by the
protocol
28. Percentage of
randomised participants
receiving allocated
intervention as intended
per protocol
The percentage of randomised
participants at the site who started
the allocated intervention, as
specified in the protocol
Percentage of randomised
participants who started
allocated intervention
Numbering of metrics refers to their position in the Delphi survey and Table 3
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Fig. 2 Worked example of site performance metrics reporting tool in Microsoft Excel. a Summary worksheet, b thresholds worksheet and c trial
data worksheet
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Our focus was mainly on publicly funded trials led by
academic researchers and our stakeholder representation
reflects this focus. We believe that we obtained a broad
and representative sample of UK-based stakeholders in-
volved in these types of clinical trials. However, it is pos-
sible that another sample, for example with respondents
from commercially led research, may have prioritised al-
ternative metrics for inclusion.
Although we sought survey respondents who had been
working in multicentre randomised trials for at least
three years, a few participants who completed all three
rounds indicated during survey registration that they did
not have this level of experience. This was due to an
error when we created the survey that allowed partici-
pants to proceed even if they reported not having at
least three years’ experience in clinical trials. However,
even if the length of experience is associated with which
metrics are viewed as important, the small number of in-
experienced participants is unlikely to have influenced
the set taken forward to the consensus meeting.
As the Delphi survey is anonymous, there is no
pressure for participants to conform. This may pre-
vent those with strong views from dominating [3],
but also means that conflicting views cannot be dis-
cussed or points explained [17, 18]. However, partici-
pants were able to provide feedback between rounds,
and we made minor clarifications to the metric defi-
nitions in response. It is possible that participation in
the consensus meeting by members of the research
team may have been unintentionally influential in dis-
cussions, which may in turn have affected voting, al-
though the meeting chairperson took care to invite
and encourage wide discussion and did not permit in-
dividuals to dominate. Finally, we acknowledge the
UK focus of this study and that other aspects of site
performance may have greater importance in other
settings.
Conclusions
By using robust methods to achieve consensus, we have
established a core set of eight metrics for measuring per-
formance of sites in multicentre randomised trials. These
metrics could improve trial conduct by helping re-
searchers to identify and address problems at sites be-
fore trials are adversely affected. Future research should
evaluate the effectiveness of using these core metrics in
monitoring trial performance.
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